COMMITTEE/SUBCOMMITTEE AMENDMENT

Bill No. HB 19 (2019)

Amendment No. 4

COMMITTEE/SUBCOMMITT	EE ACTION
ADOPTED	(Y/N)
ADOPTED AS AMENDED	(Y/N)
ADOPTED W/O OBJECTION	(Y/N)
FAILED TO ADOPT	(Y/N)
WITHDRAWN	(Y/N)

OTHER

1 2

3

4

5 6 Committee/Subcommittee hearing bill: Appropriations Committee Representative Watson, B. offered the following:

Amen	dm	en	t
			-

Remove lines 217-230 and insert:

(f) Documentation demonstrating how the program ensures or

7 does not ensure that:

8 <u>1. Canadian suppliers participating in the program are of</u>
9 <u>high quality, of high performance, and in full compliance with</u>
10 <u>relevant Canadian federal and provincial laws and regulations;</u>
11 <u>2. Prescription drugs imported under the program are not</u>
12 <u>shipped, sold, or dispensed outside of the state once in the</u>
13 <u>possession of the importer;</u>

14 <u>3. Prescription drugs imported under the program are pure,</u> 15 unadulterated, potent, and safe;

567427 - h0019-WatsonB4.docx

Published On: 3/17/2019 6:01:14 PM

COMMITTEE/SUBCOMMITTEE AMENDMENT

Bill No. HB 19 (2019)

Amendment No. 4

16	4. The program does not put consumers at a higher health
17	and safety risk than if the program did not exist;
18	5. The program provides cost savings to the state on
19	imported prescription drugs;
20	6. The program prevents the occurrence of injuries and
21	deaths associated with prescription drugs imported from outside
22	of the United States;
23	7. The purchase of prescription drugs from outside of the
24	United States does not result in lost taxes or revenue for state
25	and federal governments;
26	8. There are regulatory controls over Canadian suppliers
27	that provide substandard or dangerous prescription drugs; and
28	9. There are remedies for individuals participating in the
29	program who are injured or harmed by substandard or dangerous
30	prescription drugs.
l	567427 - h0019-WatsonB4.docx
	Published On: 3/17/2019 6:01:14 PM
	Page 2 of 2